Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?

G. Papa, S. Tura, F. Mandelli, M. L. Vegna, D. Defazio, P. Mazza, P. L. Zinzani, R. Simoni, O. DePita, G. Ferranti, P. L. Ghetti, D. Criscuolo

Research output: Contribution to journalArticlepeer-review


This study was designed to evaluate the therapeutic efficacy and toxicity of recombinant interferon alpha-2a (rIFN alfa-2a) given as initial systemic therapy in untreated mycosis fungoides and/or Sezary's syndrome patients, at a slowly escalating schedule up to the maximal tolerated dose. At the same time this schedule was administered in patients who had relapsed or were refractory to previous treatment: 28 newly diagnosed and 15 previously treated patients entered the study. IFN was given daily with dose escalation from 3 to 18 MU. The last follow-up in June 1990 indicates that 90% of previously untreated patients who obtained a complete remission remain in continuous complete remission after 18 to 40 months and that 75% of previously untreated patients who obtained partial remission remain in partial remission after 20-44 months. The event-free survival projected, calculated using the Kaplan and Meier product limit technique, was 21% of all patients at 54.7 months (40% in the previously untreated groups and 14% in the previously treated group: P = 0.12). In conclusion, interferon is very effective as a single agent in cutaneous T-cell lymphomas.

Original languageEnglish
Pages (from-to)48-51
Number of pages4
JournalBritish Journal of Haematology, Supplement
Issue number1
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?'. Together they form a unique fingerprint.

Cite this